In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1 weight loss medications Ozempic and Wegovy. The offering was immensely popular and helped ...

It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ... But some recent Hims and Hers reviews complain about ...

Its compounded semaglutide product was never the be-all and end-all for Hims & Hers ... This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before ...

The company says its semaglutide injections are fulfilled and shipped from Hims & Hers' affiliated pharmacies ... touched on delays to a COVID-19 shot review. A new AI-powered solution from ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Hims saw massive revenue growth in 2024 as it sold compounded versions of Novo Nordisk’s semaglutide. This is the clinical name for Novo’s Wegovy and Ozempic. The FDA allowed this because ...

Learn More » Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

Hims & Hers stock has slumped 40% since the U.S. FDA on February 21 removed Novo Nordisk's top-selling Wegovy and diabetes drug Ozempic, both known chemically as semaglutide, from its shortage list.

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...